Therapeutically relevant concentrations of IFN-β, a standard fist-line immunomodulatory treatment for MS, leads to induction of IDO mRNA and a significant increase in the production of QUIN by human monocyte-derived macrophages (Guillemin et al., 2001). The gene discussed is IDO1; the disease is myeloid sarcoma.